CN102526397A - Medicament for treating salivation - Google Patents
Medicament for treating salivation Download PDFInfo
- Publication number
- CN102526397A CN102526397A CN2012100080312A CN201210008031A CN102526397A CN 102526397 A CN102526397 A CN 102526397A CN 2012100080312 A CN2012100080312 A CN 2012100080312A CN 201210008031 A CN201210008031 A CN 201210008031A CN 102526397 A CN102526397 A CN 102526397A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- sialorrhea
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010039424 Salivary hypersecretion Diseases 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 208000026451 salivation Diseases 0.000 title abstract 3
- 239000000843 powder Substances 0.000 claims abstract description 9
- 208000008630 Sialorrhea Diseases 0.000 claims description 20
- 241000628997 Flos Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 239000009286 sanguis draxonis Substances 0.000 claims description 5
- 241000220433 Albizia Species 0.000 claims description 4
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 235000011468 Albizia julibrissin Nutrition 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241001148495 Cibotium barometz Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 201000009408 aspiration pneumonitis Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a powder preparation for treating salivation. The powder preparation is prepared from the following crude medicaments in parts by weight: 3 to 8 parts of cibotium barometz, 4 to 8 parts of tangerine peel, 3 to 6 parts of angelica, 2 to 5 parts of albizia julibrissin, 3 to 6 parts of fructus lycii, 1 to 10 parts of dragon blood, 3 to 6 parts of panax pseudo-ginseng, 2 to 6 parts of ligusticum chuanxiong, 1 to 4 parts of herba lycopodii, 3 to 7 parts of licorice and 2 to 6 parts of radix paeoniae alba. The powder preparation comprises simple components, is low in cost, has ideal curative effects, and can achieve remarkable curative effects on the salivation.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicament of treating sialorrhea.
Background technology
In psychiatric department was clinical, the side effect of the sialorrhea that psychosis causes was common, and treated thorny.In psychiatric department was clinical, the side effect of the sialorrhea that psychosis causes was common, and treated thornyly, and the untoward reaction of drug-induced sialorrhea also is the problem that can not be ignored in clinical care.Saliva liquid is exposed to the health that the stench that forms in the air not only influences the ward, and the patient makes hospital's respiratory tract infection rate high if in sleep, suck or anti-sialorrhea liquid is prone to cause aspiration pneumonitis.
Summary of the invention
The purpose of this invention is to provide a kind of medicament of treating sialorrhea.
In order to realize the object of the invention; The present invention provides a kind of medicament of treating sialorrhea, and it is to be processed by following materials by weight: 2～6 parts of Rhizoma Cibotii 3-8 part, 4～8 parts of Pericarpium Citri Reticulataes, 3～6 parts of Radix Angelicae Sinensis, 2～5 parts of Flos Albiziaes, 3～6 parts of Fructus Lycii, 1～10 part of Sanguis Draxonis, 3～6 parts of Radix Notoginseng, 2～6 parts of Rhizoma Chuanxiongs, 1～4 part of Herba Lycopodii, 3～7 parts in Radix Glycyrrhizae and the Radix Paeoniae Albas.
Preferably, the powder of treatment sialorrhea of the present invention is to be processed by following materials by weight: 4 parts of 5 parts of Rhizoma Cibotiis, 6 parts of Pericarpium Citri Reticulataes, 5 parts of Radix Angelicae Sinensis, 4 parts of Flos Albiziaes, 4 parts of Fructus Lycii, 5 parts of Sanguis Draxonis, 6 parts of Radix Notoginseng, 4 parts of Rhizoma Chuanxiongs, 2 parts of Herba Lycopodiis, 6 parts in Radix Glycyrrhizae and the Radix Paeoniae Albas.
Preferably, said medicament can be processed tablet, dispersible tablet, powder or capsule.Can adopt method well known to those skilled in the art to carry out preparation of medicaments.As required, can add various pharmaceutically acceptable carriers.Described carrier comprises the conventional diluent of pharmaceutical field, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant etc.Medicament of the present invention in the preparation, selectable filler has: starch, Icing Sugar, calcium phosphate, dextrin, microcrystalline Cellulose, lactose, pregelatinized Starch, mannitol etc.; Selectable binding agent has: sodium carboxymethyl cellulose, PVP-K30, hydroxypropyl cellulose, starch slurry, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, gelling starch etc.; Selectable disintegrating agent has: dried starch, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose etc.; Selectable lubricant has: magnesium stearate, Pulvis Talci, sodium lauryl sulphate, micropowder silica gel etc.
Component of the present invention is simple, with low cost, and therapeutic effect is more satisfactory, for sialorrhea apparent in view therapeutic effect is arranged.
The specific embodiment
Further specify the present invention through embodiment below.It should be understood that embodiments of the invention are to be used to explain the present invention rather than limitation of the present invention.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the present invention and requires the scope protected.
The preparation of embodiment 1 powder
Take by weighing Rhizoma Cibotii 50 grams, Pericarpium Citri Reticulatae 60 grams, Radix Angelicae Sinensis 50 grams, Flos Albiziae 40 grams, Fructus Lycii 40 grams, Sanguis Draxonis 50 grams, Radix Notoginseng 60 grams, Rhizoma Chuanxiong 40 grams, Herba Lycopodii 20 grams, Radix Glycyrrhizae 60 grams and the Radix Paeoniae Alba 40 grams and fully mix, pulverize, cross 80 mesh sieves.Take by weighing Icing Sugar 130 grams then, cross 80 mesh sieves and above-mentioned raw materials and mix, promptly get.Gained powder is divided into 100 bags.
Experimental example
Diagnostic criteria
By Chinese mental sickness classification and the 2nd edition revised edition of diagnostic criteria (sharp association of Chinese Medical Association's spirit; The CCMD-2-R of hospital of brain section of sharp university China's mental sickness classification schemes and diagnostic criteria [M] Nanjing are cured in Nanjing: publishing house of Southeast China University, 1995.20-135.) choose.Sialorrhea order of severity standard is divided 4 grades.0 minute: no sialorrhea; 1 minute: sialorrhea when only sleeping had a little mouthful water trace on medicated pillow; 2 minutes: sialorrhea during sleep, obvious moistening saliva trace is arranged on medicated pillow, wetted area is bigger; 3 minutes: sialorrhea all round the clock, even all have the saliva liquid stream to go out when speaking or sitting around, can not automatic control.
Choose and meet above-mentioned standard patient's 50 examples, wherein male 25 examples, 37 years old mean age, women 25 examples, 38 years old mean age.Be and the sialorrhea side effect occur after using psychosis, and get rid of oral inflammation, the salivary gland pathological changes causes drool.
Use the powder of the present invention of embodiment 1 preparation to treat, every day twice, each 1 bag, one month is a course of treatment.
Diagnostic criteria
Score by the diagnosis standard is judged.Treatment back sialorrhea integration reduces to 0 and is divided into recovery from illness, reduces to 1 and is divided into produce effects, reduces to 2 and is divided into improvement, and the person is invalid not subtract the branch.
Through the treatment of a course of treatment, all the patient all meets the standard of recovery from illness.And in therapeutic process, do not see obvious adverse reaction.
Claims (3)
1. medicament of treating sialorrhea; It is characterized in that it is to be processed by following materials by weight: 2～6 parts of Rhizoma Cibotii 3-8 part, 4～8 parts of Pericarpium Citri Reticulataes, 3～6 parts of Radix Angelicae Sinensis, 2～5 parts of Flos Albiziaes, 3～6 parts of Fructus Lycii, 1～10 part of Sanguis Draxonis, 3～6 parts of Radix Notoginseng, 2～6 parts of Rhizoma Chuanxiongs, 1～4 part of Herba Lycopodii, 3～7 parts in Radix Glycyrrhizae and the Radix Paeoniae Albas.
2. the medicament of treatment sialorrhea according to claim 1; It is characterized in that it is to be processed by following materials by weight: 4 parts of 5 parts of Rhizoma Cibotiis, 6 parts of Pericarpium Citri Reticulataes, 5 parts of Radix Angelicae Sinensis, 4 parts of Flos Albiziaes, 4 parts of Fructus Lycii, 5 parts of Sanguis Draxonis, 6 parts of Radix Notoginseng, 4 parts of Rhizoma Chuanxiongs, 2 parts of Herba Lycopodiis, 6 parts in Radix Glycyrrhizae and the Radix Paeoniae Albas.
3. the medicament of treatment sialorrhea according to claim 1 and 2 is characterized in that, said medicament can be processed tablet, dispersible tablet, powder or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210008031 CN102526397B (en) | 2012-01-12 | 2012-01-12 | Medicament for treating salivation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210008031 CN102526397B (en) | 2012-01-12 | 2012-01-12 | Medicament for treating salivation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526397A true CN102526397A (en) | 2012-07-04 |
| CN102526397B CN102526397B (en) | 2013-06-05 |
Family
ID=46335217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210008031 Expired - Fee Related CN102526397B (en) | 2012-01-12 | 2012-01-12 | Medicament for treating salivation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526397B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04193823A (en) * | 1990-11-27 | 1992-07-13 | Matsui Seiyaku Kk | Pill readily crushable with teeth and easily administrable without water |
| CN1074127A (en) * | 1993-01-04 | 1993-07-14 | 张维芬 | The removing opium poison from human body Chinese medicine preparation |
| WO2005007113A2 (en) * | 2003-07-14 | 2005-01-27 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| US20050053555A1 (en) * | 2003-07-14 | 2005-03-10 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| CN1891289A (en) * | 2006-05-26 | 2007-01-10 | 祝瑞燕 | Chinese medicine for treating by-reaction disease caused by anti-psychosis medicine, and its preparing method |
| EP2027852A1 (en) * | 2007-08-24 | 2009-02-25 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostoma |
| CN101757572A (en) * | 2010-01-19 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating infantile cerebral palsy and preparation method thereof |
-
2012
- 2012-01-12 CN CN 201210008031 patent/CN102526397B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04193823A (en) * | 1990-11-27 | 1992-07-13 | Matsui Seiyaku Kk | Pill readily crushable with teeth and easily administrable without water |
| CN1074127A (en) * | 1993-01-04 | 1993-07-14 | 张维芬 | The removing opium poison from human body Chinese medicine preparation |
| WO2005007113A2 (en) * | 2003-07-14 | 2005-01-27 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| US20050053555A1 (en) * | 2003-07-14 | 2005-03-10 | Crave Busters, Llc. | Appetite control compositions and methods of use |
| CN1891289A (en) * | 2006-05-26 | 2007-01-10 | 祝瑞燕 | Chinese medicine for treating by-reaction disease caused by anti-psychosis medicine, and its preparing method |
| EP2027852A1 (en) * | 2007-08-24 | 2009-02-25 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostoma |
| CN101757572A (en) * | 2010-01-19 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating infantile cerebral palsy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526397B (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766804B (en) | Chinese herbal composite for epistaxis treatment and preparation method thereof | |
| CN101856459B (en) | Chinese medicinal composition for treating lung carbunculosis and preparation method thereof | |
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN101947285B (en) | Buccal tablet for treating chronic pharyngitis | |
| CN101773651A (en) | Chinese medicine composition for treating headache and preparation method thereof | |
| CN101797352B (en) | Chinese medicinal composition for treating lassitude hypodynamia and preparation method thereof | |
| CN102058720B (en) | Chinese medical cataplasm for treating epidemic mumps | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN102657821A (en) | Drug for treating ovarian cyst | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN101549078A (en) | Pharmaceutical composition for treating intractable insomnia and preparation method thereof | |
| CN102526397B (en) | Medicament for treating salivation | |
| CN101199788B (en) | Medicament for treating asthma | |
| CN102657726A (en) | Medicament for treating insomnia | |
| CN102657744B (en) | Medicament for treating mastitis | |
| CN102698094B (en) | Medicament for treating female depression | |
| CN102872353B (en) | Medicament for treating hypertension dizzy | |
| CN102266482B (en) | Medicament for treating mania | |
| CN102274423A (en) | Medicament for treating anxiety | |
| CN103566147B (en) | A kind of medicine for the treatment of hypertension dizzy and preparation method thereof | |
| CN101716321A (en) | Traditional Chinese medicine composition for treating heart vessel blockage stasis disease and preparation method thereof | |
| CN105943584A (en) | Medicine for treating dental ulcer | |
| CN102552581B (en) | Medicament for treating insomnia | |
| CN102727741B (en) | Medicament for treating anxiety disorder | |
| CN102293888A (en) | Chinese medicinal composition for treating syndrome characterized by dyspnea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG Free format text: FORMER OWNER: GAO XINHUA Effective date: 20130805 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272051 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130805 Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin Address before: 272051 Shandong province Jining city wear Zhuangji wear Road No. 1 Jining city mental hospital Patentee before: Gao Xinhua |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170509 Address after: 226500, No. 999, Wanshou South Road, Rugao City, Jiangsu province (room 3A08-26, building 8, hi tech Zone, Nantong) Patentee after: Jiangsu hundred sword Pharmaceutical Technology Co., Ltd. Address before: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee before: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130605 Termination date: 20190112 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |